NADH as a cancer medicine

Abstract

We propose that NADH will exert a specific kill action against some cancers. NADH is a natural metabolite. We envisage a low side effect profile and that NADH therapy will, additionally, combat the wastage and weakness of cancer patients, which can be the cause of death in some cases. Significantly, NADH can be administered orally and has already cleared clinical trials, all be it for other pathologies.\n\nBackgroundAerobic respiration consists of glycolysis in the cytoplasm and in the mitochondria: the Krebs cycle and oxidative phosphorylation (OXPHOS) [1, 2]. It requires O2 and net yields 30 ATPs from one glucose molecule. Anaerobic respiration, consisting of glycolysis only, does not require O2 but produces merely 2 ATPs from one glucose molecule. When O2 is available, normal animal cells tend to favour aerobic respiration because of its higher ATP yield.